Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238955 | 0.90 | PLA2G2A (0.38) | PLA2G2AALDH1A1PTGER4PTGER2THRA | |
| SCHEMBL6106733 | 0.89 | PLA2G2A (0.37) | PLA2G2AALDH1A1PTGER4PTGER2THRA | |
| SCHEMBL5237705 | 0.89 | L3MBTL1 (0.37) | PLA2G2AALDH1A1MAPTRXFP1GAA | |
| SCHEMBL5233361 | 0.87 | ALDH1A1 (0.46) | PLA2G2AALDH1A1THRATHRBGAA | |
| SCHEMBL5233234 | 0.87 | PLA2G2A (0.39) | PLA2G2AALDH1A1PTGER4PTGER2THRA | |
| SCHEMBL5238974 | 0.83 | ALDH1A1 (0.36) | ALDH1A1PTGER4PTGER2THRATHRB | |
| SCHEMBL5238218 | 0.83 | ALDH1A1 (0.33) | PLA2G2AALDH1A1PTGER4PTGER2THRA | |
| SCHEMBL6106729 | 0.83 | TNF (0.41) | PLA2G2AALDH1A1GAA | |
| SCHEMBL5236817 | 0.83 | PLA2G2A (0.40) | PLA2G2ATHRATHRB | |
| SCHEMBL5238212 | 0.83 | RXFP1 (0.34) | ALDH1A1PTGER4PTGER2THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | PLA2G2A 3137/4885ALDH1A1 387/4885PTGER4 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.